Explore Regeneron's Q1 2025 earnings with updates on Dupixent growth, EYLEA challenges, FDA hurdles, and upcoming approvals.

CEO Sanj Patel highlighted that Kiniksa achieved $137.8 million in net product revenue for ARCALYST during Q1 2025, marking a 75% increase year-over-year. This success was attributed to robust ...

We recently published a list of Did Jim Cramer Nail All These 9 Stock Predictions?w. In this article, we are going to take a ...

Regeneron missed Wall Street estimates for first-quarter results on Tuesday, hurt by waning demand for its blockbuster eye ...

However, profits are projected to grow at a slower pace, with a rise of only 0.7% YoY. TCS Q4 Results: Profit falls 2% YoY to Rs 12,224 crore, misses estimates TCS posted a 1.7% year-on-year drop in ...

Asian Paints Q4 Results: Weak demand drags company’s sales, profit below view Weak demand ahead of the general elections, along with price cuts taken by the company amid intense competition weighed on ...

Murray Auchincloss, chief executive officer and Kate Thomson, chief financial officer will host a question and answer session from 1pm BST/8am EDT to 2pm BST/9am EDT (approx).